For cancer patients, a diagnosis is generally followed by staging. Among other things, the stage of a cancer tells the patient and physician if the cancer has spread and if it’s metastasized to the lymphatic system or other organs, etc. This information is used to determine the course of treatment (i.e. whether the cancer is […]
In November, we acknowledged National Family Caregivers Month by releasing information for caregivers and hosting two webinars on the topics of Medical and Palliative Care Decisions and Self-Care for Caregivers. Both webinars are available on demand free of charge at curemeso.org/caregivers.
With a loved one’s diagnosis of mesothelioma, the closest family member is often catapulted into […]
Although we know that a cancer diagnosis brings with it a financial burden, we do not often speak about money when discussing the experiences of patients and caregivers. In honor of National Family Caregivers Month, Janet G., the mother of a mesothelioma survivor, has provided us with some tips for patients and families facing financial […]
On October 14, the SELLAS Life Sciences Group, a biotech company leading a Phase 2 study of the WT1 vaccine, released the study’s promising data. The Meso Foundation had funded part of the Phase 1 portion of this study, the results of which prompted the Department of Defense to also award it a large grant.
The company […]
Last week, at the World Conference on Lung Cancer, Dr. Raffit Hassan presented promising data on a novel agent, anetumab ravtansine, also known as BAY 94-9343. Anetumab ravtansine is an antibody-drug conjugate directed against the target molecule mesothelin which is highly expressed on mesotheliomas.
“Anetumab ravtansine shows encouraging efficacy in patients with advanced mesothelioma which warrants […]